AlloVir

ALVR

ATLANTA, GA – – (Globe Newswire – January 22, 2024) – – Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against AlloVir, Inc. (“AlloVir” or the “Company”) (NASDAQ: ALVR). The lawsuit alleges Defendants made materially false and misleading statements and/or failed to disclose material information regarding the Company’s business, operations, and prospects, including allegations that: (i) the posoleucel Phase 3 Studies were unlikely to meet their primary endpoints; (ii) as a result, it was likely that the Company would ultimately discontinue the posoleucel Phase 3 studies; (iii) accordingly, AlloVir overstated the efficacy and clinical and/or commercial prospects of posoleucel; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you bought AlloVir shares between March 22, 2022 and December 21, 2023, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Joshua Karr, Esq. at jkarr@holzerlaw.com or Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/allovir/ to learn more.

The deadline to ask the court to be appointed lead plaintiff in the case is March 19, 2024.

Registration Deadline

Lead Plaintiff Deadline Has Passed

March 19, 2024

Submit Your Information

Name(Required)
Address
Shares Purchased(Required)
Date of Shares Purchased
Number of Shares Acquired
Acquisition Price Per Share
 
Shares Sold
Date of Shares Sold
Number of Shares Sold
Selling Price Per Share